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Abstract
Background: Concurrent sexually transmitted infections (STIs) increase the likelihood of HIV transmission. The levels
of defensins are frequently elevated in genital fluids from individuals with STIs. We have previously shown that
human defensins 5 and 6 (HD5 and HD6) promote HIV entry and contribute to Neisseria gonorrhoeae-mediated
enhancement of HIV infectivity in vitro. In this study, we dissect the molecular mechanism of the HIV enhancing
effect of defensins.
Results: HD5 and HD6 primarily acted on the virion to promote HIV infection. Both HD5 and HD6 antagonized the
anti-HIV activities of inhibitors of HIV entry (TAK 779) and fusion (T-20) when the inhibitors were present only
during viral attachment; however, when these inhibitors were added back during viral infection they overrode the
HIV enhancing effect of defensins. HD5 and HD6 enhanced HIV infectivity by promoting HIV attachment to target
cells. Studies using fluorescent HIV containing Vpr-GFP indicated that these defensins enhanced HIV attachment by
concentrating virus particles on the target cells. HD5 and HD6 blocked anti-HIV activities of soluble
glycosaminoglycans including heparin, chondroitin sulfate, and dextran sulfate. However, heparin, at a high
concentration, diminished the HIV enhancing effect of HD5, but not HD6. Additionally, the degree of the HIV
enhancing effect of HD5, but not HD6, was increased in heparinase-treated cells. These results suggest that HD5
and haparin/heparan sulfate compete for binding to HIV.
Conclusions: HD5 and HD6 increased HIV infectivity by concentrating virus on the target cells. These defensins
may have a negative effect on the efficacy of microbicides, especially in the setting of STIs.
Background
There were an estimated 33 million people living with
HIV in 2007, and there were 2.7 million new HIV infec-
tions, with the predominant mode of infection being
sexual transmission (UNAIDS 2008). Currently, there is
no effective vaccine or microbicide available to prevent
HIV spread. According to CDC data in 2008, approxi-
mately 56,000 people become newly infected with HIV
every year in the U.S. It was estimated that more than
21% of the 1.1 million infected individuals in the U.S.
are unaware of their infection. While the spread of HIV
is inefficient, sexually transmitted infections (STIs) are
known to increase the likelihood of HIV transmission
[1-5].
Defensins are antimicrobial peptides important to
innate mucosal immunity [6-9]. Indeed, the levels of
defensins in genital fluid are frequently elevated in
individuals with STIs [10-13], suggesting a potential
role of defensins in modulating HIV transmission.
Recently, antimicrobial peptides including human neu-
trophil defensins 1-3 (HNPs 1-3) and LL-37 have been
found to be increased in cervicovaginal secretions from
women with STIs and are independently associated
with increased HIV acquisition [14]. While HNPs 1-3
and LL-37 exhibit anti-HIV activities in vitro (reviewed
in [15,16]), other human alpha-defensins such as
human defensins 5 and 6 (HD5 and HD6), enhance
HIV infectivity in vitro [17]. Increased levels of HD5
have been reported in urethral secretions of men with
Neisseria gonorrhoeae and Chlamydia trachomatis
infection [12] and in cervicovaginal secretions from
women with bacterial vaginosis (BV) [18], indicating a
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sion by STIs and BV.
HD5 and HD6 are constitutively expressed by intest-
inal Paneth cells and play an important role in gut
mucosal immunity [6-9]. HD5 is also found in cervical
lavage fluid as well as in the female genital tract [18,19],
and gene expression of HD5 and HD6 can be detected
in cervicovaginal epithelial cell lines [17]. Concentra-
tions of HD5 protein ranging from 1 to 50 μg/ml have
been reported in diluted vaginal fluid from healthy
women [18,19]. We have recently shown that HD5 and
HD6 significantly enhance HIV infection at the step of
viral entry [17]. Enhancement of HIV infection was
observed with primary HIV isolates in primary CD4+ T
cells. Induction of HD5 and HD6 in response to gono-
coccal infection increased HIV infectivity, suggesting a
role of defensins in STI-mediated increased HIV trans-
mission [17]. Importantly, our recent in vitro study has
shown that HD5 and HD6 can antagonize anti-HIV
activity of polyanionic microbicides including PRO2000,
cellulose sulfate, and carrageenan [20]. These polyanio-
nic microbicides failed to protect women against HIV
infection in several clinical trials [21-23]. Although the
contributions to the ineffectiveness of these microbicides
are likely multifactorial, mucosal host factors such as
HD5 and HD6 may have a potential negative effect on
the efficacy of microbicides.
Here, we dissected the molecular mechanisms by
which HD5 and HD6 enhance HIV infectivity. Our
results demonstrated that HD5 and HD6 promoted HIV
attachment. Both HD5 and HD6 negated anti-HIV activ-
ities of soluble glycosaminoglycans (GAGs), although
HD5, but not HD6, may compete with heparin/heparan
sulfate for binding to HIV. The consequence of elevated
levels of defensins in response to STIs may lead not
only to increased susceptibility to HIV infection, but
also to ineffectiveness of polyanion-based microbicides.
Results
Pre-incubation of HIV with defensins significantly
increased HIV infection
We have previously shown that HD5 and HD6 increase
HIV infection when HIV is pre-treated with defensins
[17]. Additionally, defensins do not affect HIV infection
after cells are exposed to the virus, suggesting that these
peptides act on HIV entry. To dissect the mechanism of
this HIV enhancing effect, we first examined whether
defensins enhanced HIV infection by acting on the virion
or the target cell. Pseudotyped HIV-1JR-FL luciferase repor-
t e rv i r u sw a si n c u b a t e dw i t hH D 5o rH D 6f o r1h o u r
before addition to PHA-activated primary CD4+ T cells
(Figure 1A) or HeLa-CD4-CCR5 cells (Figure 1B). After 2
hours of incubation, infected cells were washed and cul-
tured for 48 hours before measurement of luciferase
activity. To assess the effect of defensins on the target cell,
activated primary CD4+ T cells (Figure 1A) or HeLa-CD4-
CCR5 cells (Figure 1B) were treated with defensins for 1
hour followed by washing extensively before exposure to
pseudotyped HIV-1JR-FL luciferase reporter virus for 2
hours. Luciferase activity was determined 48 hours after
infection. HIV infection was significantly increased by 6 to
15-fold with HD5 and by 23 to 37-fold with HD6 in both
primary CD4+ T cells and HeLa-CD4-CCR5 cells when
the HIV virion was pre-incubated with defensins. Note
that the degree of HIV enhancing effect of defensins (20
μg/ml, equivalent to 5.6 μMf o rH D 5a n d5 . 4μMf o r
HD6) varied from 6 to 40-fold, possibly due to the differ-
ent virus stocks and the target cell condition (e.g. cell pas-
sage). Nevertheless, the results of enhancement of HIV
infection by HD5 and HD6 were consistent. HD5 did not
increase HIV infection when cells were pre-treated with
defensins. HD6 slightly promoted HIV infection of acti-
vated CD4+ T cells (by ~3-fold), but had no effect on HIV
infection of HeLa-CD4-CCR5 cells. The degree of
Figure 1 HD5 and HD6 enhanced HIV infectivity by targeting
the virus. Pseudotyped HIV-1JR-FL luciferase reporter virus was
incubated with or without HD5 or HD6 (20 μg/ml) at 37°C for 1
hour followed by infection of primary CD4+ T cells (A) or HeLa-CD4-
CCR5 cells (B) as described in Materials and Methods. To determine
the effect of defensins on the target cell, primary CD4+ T cells or
HeLa-CD4-CCR5 cells were incubated with defensins in the presence
of FBS for 1 hour, washed, and exposed to pseudotyped HIV-1JR-FL
reporter virus for 2 hours. Cells were washed and cultured for 48
hours before measuring luciferase activity. Difference between
defensin-treated virions and non-treated control was significant (*p
< 0.05) as calculated by two-tailed, paired Student t test. The value
of mean luciferase readout is shown. Data are means ± SD of
triplicate samples and represent three independent experiments.
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cantly higher when the HIV virion was pre-incubated with
defensin compared to pre-incubation of cells. We con-
clude that HD5 and HD6 primarily acted on the virion to
achieve their HIV enhancing effect.
HD5 and HD6 negated the activity of HIV entry and
fusion inhibitors
Because HD5 and HD6 promote HIV entry, we
addressed whether these defensins interfered with anti-
HIV activities of inhibitors for HIV entry and fusion.
HeLa-CD4-CCR5 cells were pretreated with TAK779,
which is a small molecule targeting HIV co-receptor
CCR5, or were pretreated with T-20, which blocks HIV
fusion. Cells without treatment with HIV inhibitors
were also prepared as a control. Pseudotyped HIV-1JR-FL
luciferase reporter virus was incubated with or without
defensins for 1 hour. The virus mixture was then added
to the pretreated target cells and incubated for 2 hours.
Cells were washed and cultured for 48 hours either in
the absence (Figure 2B) or presence of added back HIV
inhibitor (Figure 2C). As expected, TAK779 and T20
inhibited HIV infection, and the inhibitory effect was
more potent (more than 99%) when the inhibitors were
added back after viral attachment (Figure 2A). When
HIV inhibitors were present only at the step of viral
attachment, HD5 and HD6 abolished anti-HIV activities
of TAK779 and T20 (Figure 2B). However, TAK779 and
T20 overrode the HIV enhancing effect of defensins
w h e nt h ei n h i b i t o r sw e r ea d d ed back after viral attach-
ment (Figure 2C). These results indicated that mucosal
innate effectors such as HD5 and HD6 could negatively
impact the efficacy of entry and fusion inhibitors under
certain conditions.
HD5 and HD6 increased HIV attachment to target cells
To delineate specific steps of the HIV life cycle influ-
enced by defensins, we investigated the effect of HD5
a n dH D 6o nH I Va t t a c h m e n ta t4 ° Ca n d3 7 ° C .I n c u b a -
tion at 37°C leads to HIV internalization by target
cells. Pseudotyped HIV-1 JR-FL luciferase reporter virus
was incubated in the presence or absence of defensins
for 1 hour. As a comparison, we also included identi-
cally charged linear, unstructured analogs of HD5 and
HD6, [Abu]HD5 and [Abu]HD6 [24]. We have pre-
viously shown that [Abu]HD5 and [Abu]HD6 do not
exert any HIV enhancing effect [17]. The virus-defen-
sin mixture was added to HeLa-CD4-CCR5 cells at 4°C
or at 37°C for 1 hour. Unbound virus was washed
extensively before measurement of cell-associated HIV
p24 by ELISA. HD5 and HD6 enhanced HIV attach-
ment at 4°C or at 37°C to both activated CD4+ T cells
(Figure 3A) and HeLa-CD4-CCR5 cells (Figure 3B).
The linear analogs [Abu]HD5 and [Abu]HD6 did not
exhibit any effect on HIV attachment to target cells
(Figure 3B), indicating that the enhancing effect of
defensins on HIV attachment required a properly
folded structure of defensins.
To further confirm the enhancement of HIV attach-
ment by defensins, fluorescent HIV virions containing
Vpr fused with green fluorescent protein (GFP) were
treated with or without HD5 or HD6 followed by incu-
bation with target cells at 4°C. HIV attachment was
assessed by FACS analysis or confocal microscopy.
Figure 2 HD5 and HD6 negated the activity of HIV entry and fusion inhibitors. HeLa-CD4-CCR5 cells were pre-treated with or without TAK-
779 (2 μM) or T-20 (200 nM) for 1 hour. Pseudotyped HIV-1JR-FL virus was incubated with HD5 or HD6 at 20 μg/ml at 37°C for 1 hour. The virus
mixture was then added to HeLa-CD4-CCR5 cells in the presence or absence of inhibitors for 2 hours. After washing off unbound virus, infected
cells were cultured in the (B) absence (wash off) or (C) presence (add back) of the inhibitors (TAK-779 or T-20) for 48 hours before measurement
of luciferase activity. Differences between HIV inhibitor-treated samples vs no inhibitor control in panel A were significant (*p < 0.05). Difference
between samples with and without treatment of defensins in panel B was also significant (*p < 0.05). When HIV inhibitors were added back to
the cells after viral attachment at 37°C, the difference between samples with and without defensin treatment was not significant (#p > 0.05).
Data are means ± SD of triplicate samples and represent three independent experiments.
Rapista et al. Retrovirology 2011, 8:45
http://www.retrovirology.com/content/8/1/45
Page 3 of 10Although a previous report by Zhang et al. [25] demon-
strated the attachment of fluorescent virions to CHO
cells in the absence of serum using deconvolution
microscopy, in our experiment there was no detectable
signal in cells with exposure to HIV-1JR-FL Vpr-GFP
virus in the presence of FBS, determined by FACS ana-
lysis or confocal microscopy. Interestingly, the fluores-
cent signal was significantly increased on cells with
exposure to defensin-treated virus (Figure 4A). Similarly,
the attachment of HIV-1JR-FL Vpr-GFP virus to cells was
not apparent when the fluorescent virions were not trea-
ted with defensins (Figure 4B left panel). However,
fluorescent dots were evident on cells with exposure to
defensin-treated virions (Figure 4B), suggesting that
defensins concentrated the virions on the target cell.
The role of glycosaminoglycans (GAGs) in defensin-
mediated enhancement of HIV infection
GAGs such as heparan sulfate and chondroitin sulfate,
which are widely expressed on the cell surface, are
Figure 3 HD5 and HD6 enhance HIV attachment to target cells. Pseudotyped HIV-1JR-FL virus was incubated with HD5 or HD6 at 20 μg/ml
as well as their linear analogs, [Abu]HD5 and [Abu]HD6, at 37°C for 1 hour, added to (A) PHA-activated primary CD4+ T cells (5 × 10
5 per
sample) or (B) HeLa-CD4-CCR5 cells (5 × 10
4 per sample). Cells were incubated with defensins at 4°C or 37°C for 1 hour, washed extensively with
PBS and lysed with Triton X-100. The level of cell-associated HIV p24 was determined by ELISA. Difference between defensin-treated virions and
non-treated control was significant (*p < 0.05), whereas the difference between samples with and without treatment with linear peptides [Abu]
HD5 and [Abu]HD6 was not significant (#p > 0.05). Data are means ± SD of triplicate samples and represent three independent experiments.
Figure 4 HD5 and HD6 promote attachment of fluorescent Vpr-GFP-labeled virions to the target cells.P s e u d o t y p e dH I V - 1 JR-FL virus
containing Vpr-GFP was incubated with or without HD5 and HD6 at 20 μg/ml at 37°C for 1 hour before addition to HeLa-CD4-CCR5 cells. After
2 hours incubation at 4°C, cells were extensively washed with cold-PBS, fixed, and analyzed by FACS (A) or microscopy (B). In panel A, the gray
histogram represents the signal from samples without defensins, whereas the open histogram represents the signal from cells with exposure to
defensin-treated fluorescent HIV. In panel B (magnification, 40X), white arrows indicate concentrated fluorescent HIV.
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investigated the role of soluble GAGs including heparin,
chondroitin sulfate, and dextran sulfate in defensin-
mediated enhancement of HIV infection. In agreement
with previous reports [28-32], heparin, chondroitin sulfate,
and dextran sulfate exhibited anti-HIV activities (Figure
5A-C, left panels). HD5 at 20 μg/ml abolished anti-HIV
activity of heparin at 0.1 μg/ml (equivalent to 6 nM, based
on the molecular weight of 16 kD), but not at higher con-
centrations (10 and 100 μg/ml) (Figure 5A. middle panel).
In contrast, HD6 at 20 μg/ml abolished anti-HIV activities
of heparin at all tested concentrations of heparin (Figure
5A, right panel). Both HD5 and HD6 blocked anti-HIV
activity of chondroitin sulfate, although chondroitin sulfate
at 100 μg/ml reduced the HIV enhancing effect of HD5
and HD6 (Figure 5B). Similarly, HD5 and HD6 abolished
anti-HIV activity of dextran sulfate (Figure 5C), although
dextran sulfate at 100 μg/ml completely attenuated the
HIV enhancing of HD5 and reduced the effect of HD6 by
60%. These results indicate that GAGs more effectively
attenuated the HIV enhancing effect of HD5 than of HD6.
To determine the impact of cell-associated GAGs on
the enhancement of HIV infection by defensins, HeLa-
CD4-CCR5 cells were treated with heparinase I, which
Figure 5 Effect of soluble GAGs on defensin-mediated enhancement of HIV infectivity. Pseudotyped HIV-JR-FL virus was incubated with or
without HD5 or HD6 at 20 μg/ml in the absence or presence of heparin (A), chondroitin sulfate (B), and dextran sulfate (C) at various
concentrations. After washing off unbound virus, infected cells were cultured for 48 hours before measurement of luciferase activity. Anti-HIV
activities of soluble GAGs in the absence of defensins are shown in the left panel. Black bars represent the effect of soluble GAGs on HIV
enhancement by HD5 (middle panels) and HD6 (right panels). Open bars (in the middle panel) represent samples in the absence of defensins. In
the left panels, the difference between soluble GAG-treated virions and non-treated control is significant (*p < 0.05). In the middle and right
panels, the difference between samples with or without defensins is significant (**p < 0.05) except samples treated with heparin at 10 or 100
μg/ml or dextran sulfate at 100 μg/ml in the presence of HD5 (#p > 0.05). After Bonferroni correction, the difference between heparin (1 μg/ml)-
treated samples with or without HD5 was not significant (+, p = 0.06). Similarly, the difference between condroitin sulfate (100 μg/ml)-treated
samples with or without HD5 was not significant (x, p = 0.14) after Bonferroni correction. Data are means ± SD of triplicate samples and
represent three independent experiments.
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attachment [33]. Cells were washed with PBS and then
exposed to HIV with or without defensin treatment. As
expected, heparinase treatment significantly reduced
HIV infection by 73-84% (Figure 6 and data not shown).
The degree of enhancement of HIV infection by HD5
was further increased in heparinase-treated target cells
by 2-fold compared to that in cells without heparinase
treatment. In contrast, heparinase treatment did not
affect the HIV enhancing effect of HD6. These results
suggest that HD5 and heparin/heparan sulfate may com-
pete for the same regions of HIV.
Discussion
We demonstrated that HD5 and HD6 enhanced HIV
infectivity by promoting virion attachment, a rate-limit-
ing step of HIV entry [34]. These defensins appeared to
increase HIV attachment by concentrating virions on
the target cell. HD5 and HD6 negated the anti-HIV
activity of HIV entry and fusion inhibitors, TAK 779
and T20 when the inhibitors were present only during
viral attachment. While both defensins antagonized anti-
HIV activities of several soluble GAGs, the HIV enhan-
cing effect of HD5, but not HD6, was sensitive to
heparin at higher concentrations. Additionally, the
removal of cell-associated heparin/heparan sulfate led to
an increase in enhancement of HIV infection by HD5,
but not HD6, suggesting that these two defensins inter-
act differently with HIV.
Alpha-defensins are structurally similar, despite their
moderate sequence identity and distinct cellular func-
tions [35]. For example, unlike all other alpha-defensins,
HD6 exhibits little antibacterial activity [36]. HNPs1-4
inhibit HIV infection [15,37], whereas HD5 and HD6
promote HIV infection [17]. Although both HD5 and
HD6 are Paneth cell defensins, their amino acid
s e q u e n c e sh a v el i t t l eh o m o l o g yb e y o n daf e wc o n s e r v e d
residues: six Cys residues, an Arg-Glu salt bridge [38],
and an invariant Gly residue [39]. These results suggest
that specific residues in defensins may make subtle con-
tributions to their structures resulting in distinct func-
tions. Defensins may aggregate virions through
oligomerization as illustrated by the recently reported
self-association ability of HD5 [40], and HD6 may
assemble into an elongated, high-order helical structure
[35]. The structural findings are consistent with our
observation that HD6 has a strong tendency to self-
associate in solution and to form high-order aggregates
on target molecules (personal communication to W.
Lu). We speculate that higher-order HD6 aggregates
and the lack of HD6 structural amphipathicity, while
debilitating its productive interactions with many mole-
cular, bacterial, and viral targets [41,42], is ideally suited
for “cross-linking” HIV virions and the target cell.
Further analysis of the molecular determinants mediat-
ing the HIV enhancing effect of HD5 and HD6 will pro-
vide a better understanding of the relationship between
structure–and specific residues in particular–and the
HIV enhancing function.
Heparin modulated the effect of HD5, but not HD6,
on HIV infection. The net positive charge of HD5 (+4)
is higher than that of HD6 (+2); thus, a simple net
charge neutralization is unlikely to explain the inhibition
of HD5-mediated HIV enhancement by heparin. We
observed differences in their dimer structures and elec-
trostatic surface potentials ([35] and Figure 7). The elec-
trostatic surface potentials of HD5 and HD6 monomers
were previously described [35]. We note that the HD5
and HD6 homodimers display significantly different
electrostatic surface potentials from one another, and
that HD6 dimerization generates an electropositive cleft
not observed in the HD5 homodimer (Figure 7). Both
charge and hydrophobicity are known to contribute to
binding of a protein to heparin [43]. Hydrophobicity
rather than cationicity has been recently shown to play
a dominant role in the killing of Gram-positive bacteria,
inhibition of anthrax lethal factor, and binding of HIV
gp120 by HNP-1 [44]. While other defensins such as
HNP-1, HNP-4, and HBD3 interact with heparin and
heparan sulfate [45], the binding of HD5 and HD6 to
heparin remains to be determined. Further studies on
specific residues in defensins are required to elucidate
the role of cationicity and hydrophobicity in the binding
Figure 6 Defensin-mediated enhancement of HIV infection in
heparinase I-treated cells. HeLa-CD4-CCR5 cells were treated with
heparinase I at 37°C for 2 hours to remove cell-associated heparin
and heparan sulfate (3:1). Cells were washed followed by exposure
to defensin-treated pseudotyped HIV-JR-FL luciferase reporter virus for
2 hours. Infected cells were cultured for 48 hours. Difference
between samples in cells with or without heparinase treatment was
indicated (*, p<0.05). Data are means ± SD of triplicate samples and
represent two independent experiments.
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that heparin and HD5 may bind to the same regions of
HIV gp120. Heparin is known to bind to the V3 loop
and to the CD4 induced site of HIV gp120
[27,31,33,46]. Thus, identification of specific regions of
HIV gp120 proteins that interact with HD5 and HD6
would likely clarify the interplay between defensins and
polyanionic polymers such as heparin and polyanionic
microbicides.
The semen-derived enhancer of viral infection peptide
(SEVI) has been shown to significantly enhance HIV
infectivity, implicating its involvement in sexual trans-
mission of HIV at the mucosa [47]. SEVI promotes
binding of HIV-1 R5 and X4 virus to target cells [47].
Figure 7 Electrostatic surface potentials of HD5 and HD6 homodimers. Monomers A and C of PDB 1ZMP were used to generate the HD5
homodimer, and monomers A and B of PDB 1ZMQ were used to generate the HD6 homodimer [35]. Electrostatic potentials were calculated
using APBS [52] and displayed on the solvent-accessible surface. Electronegative and electropositive surfaces are colored red and blue,
respectively, and contoured from -3 to +3 kT/e.
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fate, but not chondroitin sulfate, block the HIV enhan-
cing effect of SEVI peptides [48]. We have previously
shown that the HIV enhancing effect of HD5 and HD6
is more pronounced with R5 virus compared to X4
virus [17], suggesting the clinical significance of defen-
sins as R5 viruses are almost exclusively detected upon
sexual transmission. In contrast to SEVI peptides, HD5
and HD6 promoted HIV infectivity in the presence of
these polyanionic polymers (albeit high concentrations
of heparin inhibit HD5). After the disappointing results
of trials using candidate polyanion microbicides, anti-
retroviral drug based microbicides have become the cur-
rent focus in microbicide development. A recent report
indicated that a gel containing 1% tenofovir reduced
HIV acquisition by an estimated 39% overall, and by
54% in women with high gel adherence [49]. Our stu-
dies on the interplay between defensins and HIV inhibi-
tors, such as TAK779 and T20, suggest that the
presence of sufficient amounts of HIV inhibitors during
viral infection and high adherence are required to main-
tain the efficacy of topical microbicides in overcoming
the HIV enhancing effect of endogenous peptides at the
vaginal mucosa.
In conclusion, we demonstrated that HD5 and HD6
promoted HIV infectivity by enhancing the attachment
of HIV to target cells. Understanding the complex func-
tions of these mucosal host factors in HIV transmission
is crucial for the development of new strategies for HIV
prevention, especially in the setting of STIs.
Materials and methods
Reagents
HD5 and HD6, as well as linear unstructured forms of
HD5 and HD6, [Abu]HD5 and [Abu]HD6, in which the
six cysteine residues were replaced by isosteric a-amino-
butyric acid (Abu), were chemically synthesized and
folded as described previously [24]. The molecular mass
of the peptides was verified by electrospray ionization
mass spectrometry (ESI-MS) as described previously
[24]. Both synthetic HD5 and HD6 were correctly folded
as indicated by structural analysis by X-ray crystallogra-
phy [35]. Heparin, chondroitin sulfate, dextran sulfate,
and heparinase I were purchased from Sigma (St. Louis,
IN).
Cell culture
Peripheral blood mononuclear cells (PBMC) from nor-
mal healthy blood donors were isolated by Ficoll-Hypa-
que gradient centrifugation. CD4
+ T cells were isolated
from PBMCs by negative selection using a CD4
+ Tc e l l
isolation kit from Miltenyi Biotech (Auburn, CA). The
purity of cells was 98% based on flow cytometric analy-
sis. CD4
+ T cells were stimulated with
phytohemagglutinin (PHA) at 5 μg/ml and maintained
in RPMI medium supplemented with 10% fetal bovine
serum (FBS) and 25 units/ml IL-2 for 3 days at 37°C
prior to viral infection. HeLa-CD4-CCR5 cells were pro-
vided by David Kabat (University of Oregon, Portland)
and maintained in Dulbecco’s minimal essential medium
(DMEM) containing 10% FBS.
HIV-1 infection
Replication-defective HIV-1 luciferase-expressing repor-
ter viruses, pseudotyped with HIV-1JR-FL (gift of D. Litt-
man, New York University) for a single-cycle infection
assay, were produced as described previously [50,51].
Briefly, HEK293T cells were co-transfected with a plas-
mid encoding the envelope-deficient HIV-1 NL4-3 virus
with the luciferase reporter gene inserted into nef
(pNL4-3.Luc.R-E-, AIDS Research & Reference Reagent
Program, ARRRP, National Institute of Allergy and
Infectious Disease, National Institutes of Health, from
N. Landau, New York University) and a pSV plasmid
expressing the JR-FL glycoprotein. The supernatant was
collected 48 hours after transfection, and filtered. Virus
stocks were analyzed for HIV-1 p24 antigen by ELISA
(SAIC Frederick, Frederick, MD). To produce HIV-1JR-
FL pseudotyped viruses in the absence of serum, trans-
fection was performed as described above. Transfected
cells were incubated for 24 h, washed with PBS, and cul-
tured in medium without serum for an additional 24 h
prior to collecting viruses.
To assess whether defensins enhanced HIV infection
by acting on the virions, serum-free pseudotyped HIV-
1JR-FL luciferase reporter viruses were incubated with
defensins at 20 μg/ml at 37°C for 1 hour. FBS at a final
concentration of 10% (v/v) was added the defensin-virus
mixture before addition to HeLa-CD4-CCR5 cells,
seeded at 5 × 10
4 in a 48-well plate and grown for over-
night. After 2 h incubation, cells were washed exten-
sively and cultured for 48 hours before measuring of
luciferase activity using Luciferase Substrate Buffer (Pro-
mega Inc). Luciferase activity (relative light units; R.L.
U.) reflecting viral infection was measured on an EG &
G (Berthold) MiniLumat LB9506 luminometer.
To determine the effect of defensins on the target cell,
PHA-activated primary CD4+ T cells (1 × 10
6) or HeLa-
CD4-CCR5 cells (5 × 10
4) were treated with defensins
in the presence of FBS for 1 hour at 37°C, washed,
exposed to pseudotyped HIV-1JR-FL luciferase reporter
viruses for 2 hours, washed, and cultured for additional
48 hours.
To determine the effect of defensins on anti-HIV
activity of HIV inhibitors, HeLa-CD4-CCR5 cells were
pre-treated with or without TAK-779 (2 μM) or T-20
(200 nM) for 1 hour. Cells without HIV inhibitor treat-
ment were included as a control. Serum-free
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was incubated with HD5 or HD6 at 20 μg/ml at 37°C
for 1 hour. The virus mixture was then added to cells in
the presence or absence of inhibitors for 2 hours. After
washing off unbound virus, infected cells were cultured
in the absence (wash off) or presence (add back) of the
inhibitors for 48 hours before measurement of luciferase
activity.
To determine the effect of defensins on HIV infection
in the presence or absence of soluble GAGs, serum-free
HIV-1JR-FL pseudotyped luciferase reporter virus was
incubated with or without HD5 or HD6 in the presence
of soluble GAGs at varying concentrations at 37°C for 1
hour followed by HIV infection. The removal of cell-
associated GAGs was performed by incubating with
heparinase I (20 U/ml) for 2 hours at 37°C. Cells were
washed with PBS three times before HIV infection.
HIV attachment assay
HeLa-CD4-CCR5 cells were seeded at 5 × 10
4 per well
in 48-well plates and cultured overnight. PHA-activated
primary CD4+ T cells (5 × 10
5 per sample) were pre-
pared as described above. Serum-free pseudotyped HIV-
1JR-FL was pre-incubated in the absence or presence of
defensins for 1 h at 37°C. FBS was added the virus mix-
ture to a final concentration to 10% (v/v) before addi-
tion to cells. Cells were then incubated with virus for 2
hours at 4°C or 37°C. Cells were washed four times and
lysed with 1% Triton X-100. Cell-associated HIV p24
antigen was measured by p24 ELISA (NCI, Frederick).
To access the effect of defensins on HIV attachment
by FACS analysis, pseudotyped HIV-1JR-FL virus contain-
ing Vpr-GFP (25 ng p24) was incubated with or without
defensins for 1 hour before exposure to EDTA-sus-
pended HeLa-CD4-CCR5 cells (5 × 10
5 cell per sample)
at 4°C for 2 hours. After washing off unbound virus,
cells were fixed with 2% paraformaldehyde and analyzed
on a FACScan (Becton Dickinson, CA). Results were
analyzed with FlowJo Software (Tree Star, OR). To ana-
lyze the effect of defensins using microscopy, HeLa-
CD4-CCR5 cells at 2.5 × 10
5 cells per well were seeded
into a 4-well chamber slide and cultured overnight. The
defensin-GFP virus mixture was added to the cells and
incubated at 4°C for 2 hours. After washing off unbound
virus, cells were fixed and mounted with VECTA-
SHIELD HardSet mounting media with DAPI (Vector,
CA) and visualized using Axioplan 2 (Zeiss, Germany).
The images were analyzed using Volocity 5.2.1 (Perkin
Elmer, MA).
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